Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham R Foster

Showing results (111-120 of 191) with videos related to

Pageof 20
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 17, 2016
Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated CirrhosisZobair M Younossi, Maria Stepanova, Jordan Feld, et al.
Journal of Hepatology|February 13, 2016
Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluationNatasha K Martin, Peter Vickerman, Gregory J Dore, et al.
Plos One|July 19, 2016
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)Tarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.
The International Journal on Drug Policy|May 30, 2026
Can real-world scaling up HCV treatment in people who inject drugs be cost-saving: an economic modelling study in the UKZoe Ward, Hannah Fraser, Stuart Mc Pherson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 7, 2011
Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3Samir R Shah, Keyur Patel, Patrick Marcellin, et al.
The Lancet. Gastroenterology & Hepatology|November 28, 2018
Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trialStuart Flanagan, Jan Kunkel, Victoria Appleby, et al.
Plos One|January 6, 2017
Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic ResponseTarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.
Journal of Thrombosis and Haemostasis : JTH|March 16, 2025
Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidanceBarbara A Konkle, Flora Peyvandi, Graham R Foster, et al.
Journal of Viral Hepatitis|April 12, 2019
Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis BLai Wei, Vedran Pavlovic, Aruna T Bansal, et al.
The Journal of Infectious Diseases|August 27, 2014
Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?Upkar S Gill, Alexandra Zissimopoulos, Safa Al-Shamma, et al.
Pageof 20

Showing results (111-120 of 191) with videos related to

Sort By:
Pageof 20
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 17, 2016
Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated CirrhosisZobair M Younossi, Maria Stepanova, Jordan Feld, et al.
Journal of Hepatology|February 13, 2016
Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluationNatasha K Martin, Peter Vickerman, Gregory J Dore, et al.
Plos One|July 19, 2016
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)Tarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.
The International Journal on Drug Policy|May 30, 2026
Can real-world scaling up HCV treatment in people who inject drugs be cost-saving: an economic modelling study in the UKZoe Ward, Hannah Fraser, Stuart Mc Pherson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 7, 2011
Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3Samir R Shah, Keyur Patel, Patrick Marcellin, et al.
The Lancet. Gastroenterology & Hepatology|November 28, 2018
Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trialStuart Flanagan, Jan Kunkel, Victoria Appleby, et al.
Plos One|January 6, 2017
Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic ResponseTarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.
Journal of Thrombosis and Haemostasis : JTH|March 16, 2025
Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidanceBarbara A Konkle, Flora Peyvandi, Graham R Foster, et al.
Journal of Viral Hepatitis|April 12, 2019
Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis BLai Wei, Vedran Pavlovic, Aruna T Bansal, et al.
The Journal of Infectious Diseases|August 27, 2014
Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?Upkar S Gill, Alexandra Zissimopoulos, Safa Al-Shamma, et al.
Pageof 20